港股異動丨四環醫藥放量升超19%,即將舉行渼顏空間再生新品上市會
四環醫藥(0460.HK)午後進一步拉昇,一度升超19%報1.43港元,股價創2022年2月以來新高,截至目前成交額放大至4.9億港元。該股年內股價已經翻倍。消息面上,四環醫藥渼顏空間即將於2025年7月19日舉行再生新品上市會。據悉,依託“自研+BD”策略,四環醫藥旗下醫美平台渼顏空間已佈局覆蓋填充、塑形、光電設備及皮膚管理等60餘款產品,滿足全生命週期需求,並取得爆發式增長,2024年醫美業務收入達7.44億元,同比增長65.4%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.